NASDAQ:TRIL

Trillium Therapeutics Competitors

$9.98
-0.40 (-3.85 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$9.80
Now: $9.98
$10.42
50-Day Range
$9.86
MA: $10.75
$12.03
52-Week Range
$4.05
Now: $9.98
$20.96
Volume829,196 shs
Average Volume1.32 million shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.27

Competitors

Trillium Therapeutics (NASDAQ:TRIL) Vs. IMAB, ARNA, AGIO, AVIR, APLS, and TPTX

Should you be buying TRIL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Trillium Therapeutics, including I-Mab (IMAB), Arena Pharmaceuticals (ARNA), Agios Pharmaceuticals (AGIO), Atea Pharmaceuticals (AVIR), Apellis Pharmaceuticals (APLS), and Turning Point Therapeutics (TPTX).

I-Mab (NASDAQ:IMAB) and Trillium Therapeutics (NASDAQ:TRIL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Valuation & Earnings

This table compares I-Mab and Trillium Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$4.31 million951.50$-208,560,000.00($28.90)-1.97
Trillium Therapeutics$120,000.008,567.91$-41,620,000.00($1.38)-7.23

Trillium Therapeutics has lower revenue, but higher earnings than I-Mab. Trillium Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

16.6% of I-Mab shares are held by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares I-Mab and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
Trillium TherapeuticsN/A-70.00%-28.84%

Analyst Recommendations

This is a summary of recent recommendations and price targets for I-Mab and Trillium Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00403.00
Trillium Therapeutics01602.86

I-Mab presently has a consensus target price of $70.00, suggesting a potential upside of 22.81%. Trillium Therapeutics has a consensus target price of $21.8333, suggesting a potential upside of 118.77%. Given Trillium Therapeutics' higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than I-Mab.

Summary

Trillium Therapeutics beats I-Mab on 6 of the 11 factors compared between the two stocks.

Arena Pharmaceuticals (NASDAQ:ARNA) and Trillium Therapeutics (NASDAQ:TRIL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Volatility and Risk

Arena Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Valuation & Earnings

This table compares Arena Pharmaceuticals and Trillium Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arena Pharmaceuticals$806.43 million4.93$397.55 million$7.698.57
Trillium Therapeutics$120,000.008,567.91$-41,620,000.00($1.38)-7.23

Arena Pharmaceuticals has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.7% of Arena Pharmaceuticals shares are held by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are held by institutional investors. 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Arena Pharmaceuticals and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arena PharmaceuticalsN/A-33.17%-30.41%
Trillium TherapeuticsN/A-70.00%-28.84%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Arena Pharmaceuticals and Trillium Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arena Pharmaceuticals001503.00
Trillium Therapeutics01602.86

Arena Pharmaceuticals presently has a consensus target price of $92.80, suggesting a potential upside of 40.82%. Trillium Therapeutics has a consensus target price of $21.8333, suggesting a potential upside of 118.77%. Given Trillium Therapeutics' higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than Arena Pharmaceuticals.

Summary

Arena Pharmaceuticals beats Trillium Therapeutics on 8 of the 13 factors compared between the two stocks.

Agios Pharmaceuticals (NASDAQ:AGIO) and Trillium Therapeutics (NASDAQ:TRIL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Agios Pharmaceuticals and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agios Pharmaceuticals-170.65%-57.63%-37.15%
Trillium TherapeuticsN/A-70.00%-28.84%

Volatility and Risk

Agios Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Agios Pharmaceuticals and Trillium Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agios Pharmaceuticals03702.70
Trillium Therapeutics01602.86

Agios Pharmaceuticals presently has a consensus target price of $64.6364, suggesting a potential upside of 18.19%. Trillium Therapeutics has a consensus target price of $21.8333, suggesting a potential upside of 118.77%. Given Trillium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than Agios Pharmaceuticals.

Valuation & Earnings

This table compares Agios Pharmaceuticals and Trillium Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agios Pharmaceuticals$117.91 million32.38$-411,470,000.00($6.86)-7.97
Trillium Therapeutics$120,000.008,567.91$-41,620,000.00($1.38)-7.23

Trillium Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

92.9% of Agios Pharmaceuticals shares are held by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are held by institutional investors. 3.2% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Trillium Therapeutics beats Agios Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares Trillium Therapeutics and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/A-70.00%-28.84%
Atea PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Trillium Therapeutics and Atea Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics01602.86
Atea Pharmaceuticals00403.00

Trillium Therapeutics currently has a consensus target price of $21.8333, indicating a potential upside of 118.77%. Atea Pharmaceuticals has a consensus target price of $69.3333, indicating a potential upside of 54.28%. Given Trillium Therapeutics' higher possible upside, research analysts plainly believe Trillium Therapeutics is more favorable than Atea Pharmaceuticals.

Valuation and Earnings

This table compares Trillium Therapeutics and Atea Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium Therapeutics$120,000.008,567.91$-41,620,000.00($1.38)-7.23
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Atea Pharmaceuticals has lower revenue, but higher earnings than Trillium Therapeutics.

Insider & Institutional Ownership

67.5% of Trillium Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Trillium Therapeutics beats Atea Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares Trillium Therapeutics and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/A-70.00%-28.84%
Apellis PharmaceuticalsN/A-336.93%-78.28%

Volatility and Risk

Trillium Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Trillium Therapeutics and Apellis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics01602.86
Apellis Pharmaceuticals031112.87

Trillium Therapeutics currently has a consensus target price of $21.8333, indicating a potential upside of 118.77%. Apellis Pharmaceuticals has a consensus target price of $125.00, indicating a potential upside of 174.30%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Trillium Therapeutics.

Valuation and Earnings

This table compares Trillium Therapeutics and Apellis Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium Therapeutics$120,000.008,567.91$-41,620,000.00($1.38)-7.23
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.82

Trillium Therapeutics has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.5% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Trillium Therapeutics beats Apellis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares Trillium Therapeutics and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/A-70.00%-28.84%
Turning Point TherapeuticsN/A-23.81%-23.08%

Volatility and Risk

Trillium Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Trillium Therapeutics and Turning Point Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics01602.86
Turning Point Therapeutics00703.00

Trillium Therapeutics currently has a consensus target price of $21.8333, indicating a potential upside of 118.77%. Turning Point Therapeutics has a consensus target price of $153.7143, indicating a potential upside of 110.48%. Given Trillium Therapeutics' higher possible upside, research analysts plainly believe Trillium Therapeutics is more favorable than Turning Point Therapeutics.

Valuation and Earnings

This table compares Trillium Therapeutics and Turning Point Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium Therapeutics$120,000.008,567.91$-41,620,000.00($1.38)-7.23
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-24.42

Trillium Therapeutics has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.5% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are owned by institutional investors. 23.2% of Turning Point Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


Trillium Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59-0.8%$3.42 billion$306.98 million-6.95
Insmed logo
INSM
Insmed
1.2$33.07-1.7%$3.42 billion$136.47 million-12.72
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15-0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
MorphoSys logo
MOR
MorphoSys
0.3$22.65-2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46-5.3%$2.75 billion$260.98 million-357.67Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00-0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39-0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26-5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73-0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13-5.6%$2.35 billion$15 million-17.35Unusual Options Activity
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15-0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44-1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02-0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22-3.5%$1.94 billion$410,000.00-5.92Analyst Report
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69-4.6%$1.91 billionN/A-25.40Increase in Short Interest
MacroGenics logo
MGNX
MacroGenics
1.2$31.83-2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73-3.2%$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59-3.1%$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91-3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.